With prestigious prize, an overshadowed CRISPR researcher wins the spotlight – Science Magazine
Science Magazine |
With prestigious prize, an overshadowed CRISPR researcher wins the spotlight
Science Magazine For Šikšnys, who works at Vilnius University’s Institute of Biotechnology in Lithuania, the recognition was doubly sweet because his part in the discovery of CRISPR often has been overlooked. Šikšnys will share the $1 million award with two researchers … CRISPR scientists win prestigious $1m Kavli awardBioNews CRISPR researchers receive Kavli Prize in NanoscienceChemical & Engineering News |
NutraIngredients-usa.com |
Researchers to use CRISPR gene-editing to develop microbiome supplements for malnourished kids
NutraIngredients-usa.com The two-year collaboration will see Washington University’s Dr. Jeffrey Gordon use MilliporeSigma’s CRISPR genome-editing technology to potentially modify sequences in the DNA of microbes isolated from human gut microbiome samples. The results will … |
|
First fetus enrolled in stem–cell transplant trial
BioNews The first in utero stem cell transplant trial has welcomed its first baby – born after being treated in the womb with her mother’s stem cells. Elianna Constantino who is now four months old, underwent the in-utero procedure at the University of … |
Tech Times |
ASCO 2018: Immunotherapy in Prostate Cancer: The Path Forward
UroToday Such studies assessed the effect of addition of other accepted treatments such as enzalutamide, PARP inhibitors, Radium 223, and docetaxel, to immunotherapy. Docetaxel in fact, induces immunogenic modulations, and causes increased expression of … Immunotherapy Drug Keytruda Halts ‘Untreatable’ Prostate Cancer In Some MenTech Times Prostate cancer drug Keytruda shows positive results in a few men during first clinical trialUSA TODAY Immunotherapy could stop prostate cancer spreading, trial showsThe Guardian PharmaTimes –The European Scientist –BBC News all 69 news articles » |
Rare Disease Report |
FDA Grants Breakthrough Therapy Designation to Gene Therapy for Treatment of CALD
Rare Disease Report The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to bluebird bio, Inc.’s Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), a serious X-linked genetic disease that is rare and … |
CNBC |
AstraZeneca CEO on immunotherapy, drug prices
CNBC AstraZeneca CEO on immunotherapy, drug prices. 34 Mins Ago. Pascal Soriot, AstraZeneca CEO, speaks to CNBC’s Meg Tirrell at American Society of Clinical Oncology (ASCO) conference about the company’s immunotherapy treatments, research and … |